Recommended Augmentin Dosing for Suspected Skin Infections
For adults with suspected skin infections, prescribe Augmentin 875/125 mg twice daily (bid) for 7-10 days, taken at the start of meals to minimize gastrointestinal side effects 1, 2.
Adult Dosing
The standard oral regimen is:
- Augmentin 875/125 mg twice daily (bid) 1
- Duration: 7-10 days depending on clinical response 1
- Administration: Take at the start of meals to enhance absorption and reduce GI intolerance 2
Clinical Context Matters
The 2014 IDSA guidelines position amoxicillin-clavulanate as appropriate for:
- Animal or human bite wounds requiring coverage of both aerobic and anaerobic bacteria 1
- Mild to moderate non-purulent cellulitis when MSSA coverage is desired alongside streptococcal coverage 1
- Infections requiring activity against β-lactamase-producing organisms
Important caveat: Augmentin misses MRSA coverage 1. If you suspect MRSA (injection drug use, known colonization, severe infection with systemic signs, or penetrating trauma), you need vancomycin or another MRSA-active agent instead 1.
Pediatric Dosing (≥3 months)
For children with skin infections:
- Standard formulation: 45 mg/kg/day of amoxicillin component divided every 12 hours 2
- High-dose ES-600 formulation: 90 mg/kg/day divided every 12 hours for resistant organisms 2
- Maximum duration: 10 days 2
The ES-600 suspension contains different clavulanate ratios and cannot be substituted with standard suspensions 2.
Evidence Quality and Practical Considerations
The IDSA guidelines provide strong recommendations with moderate-quality evidence for amoxicillin-clavulanate in bite wounds 1. Research supports twice-daily dosing as equally effective to three-times-daily regimens with improved compliance and potentially fewer GI side effects due to lower total daily clavulanate exposure 3, 4.
Recent data comparing 875/125 mg bid versus 500/125 mg tid shows the tid regimen may produce greater declines in inflammatory markers in some infections 5, though the bid regimen remains standard for convenience and adherence.
Common Pitfalls to Avoid
- Don't use for purulent abscesses without drainage: Incision and drainage is primary; antibiotics are adjunctive 1
- Don't use for suspected MRSA: The drug lacks activity against methicillin-resistant staphylococci 1
- Don't substitute formulations in children: ES-600 has different clavulanate concentrations and is not interchangeable 2
- Don't prescribe on empty stomach: GI side effects (diarrhea, nausea) are significantly reduced when taken with food 2
Safety Profile
Most common adverse effects include diarrhea (12.9% in pediatric studies), vomiting (6-7%), and GI upset 2. These are generally mild to moderate. Monitor hepatic function in patients with liver disease, as hepatotoxicity can occur 2.
The 875 mg bid formulation delivers adequate tissue penetration for skin and soft tissue infections while maintaining a favorable safety profile compared to higher-frequency dosing 3, 4.